• Something wrong with this record ?

Halogen substituents enhance oxime nucleophilicity for reactivation of cholinesterases inhibited by nerve agents

T. Zorbaz, D. Malinak, T. Hofmanova, N. Maraković, S. Žunec, NM. Hrvat, R. Andrys, M. Psotka, A. Zandona, J. Svobodova, L. Prchal, S. Fingler, M. Katalinić, Z. Kovarik, K. Musilek

. 2022 ; 238 (-) : 114377. [pub] 20220427

Language English Country France

Document type Journal Article

The fluorinated bis-pyridinium oximes were designed and synthesized with the aim of increasing their nucleophilicity and potential to reactivate phosphorylated human recombinant acetylcholinesterase (AChE) and human purified plasmatic butyrylcholinesterase (BChE) in relation to chlorinated and non-halogenated oxime analogues. Compared to non-halogenated oximes, halogenated oximes showed lower pKa of the oxime group (fluorinated < chlorinated < non-halogenated) along with higher level of oximate anion formation at the physiological pH, and had a higher binding affinity of both AChE and BChE. The stability tests showed that the fluorinated oximes were stable in water, while in buffered environment di-fluorinated oximes were prone to rapid degradation, which was reflected in their lower reactivation ability. Mono-fluorinated oximes showed comparable reactivation to non-halogenated (except asoxime) and mono-chlorinated oximes in case of AChE inhibited by sarin, cyclosarin, VX, and tabun, but were less efficient than di-chlorinated ones. The same trend was observed in the reactivation of inhibited BChE. The advantage of halogen substituents in the stabilization of oxime in a position optimal for in-line nucleophilic attack were confirmed by extensive molecular modelling of pre-reactivation complexes between the analogue oximes and phosphorylated AChE and BChE. Halogen substitution was shown to provide oximes with additional beneficial properties, e.g., fluorinated oximes gained antioxidative capacity, and moreover, halogens themselves did not increase cytotoxicity of oximes. Finally, the in vivo administration of highly efficient reactivator and the most promising analogue, 3,5-di-chloro-bispyridinium oxime with trimethylene linker, provided significant protection of mice exposed to sarin and cyclosarin.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017791
003      
CZ-PrNML
005      
20221025132931.0
007      
ta
008      
220720s2022 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejmech.2022.114377 $2 doi
035    __
$a (PubMed)35526478
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Zorbaz, Tamara $u Institute for Medical Research and Occupational Health, Ksaverska Cesta 2, HR-10000, Zagreb, Croatia
245    10
$a Halogen substituents enhance oxime nucleophilicity for reactivation of cholinesterases inhibited by nerve agents / $c T. Zorbaz, D. Malinak, T. Hofmanova, N. Maraković, S. Žunec, NM. Hrvat, R. Andrys, M. Psotka, A. Zandona, J. Svobodova, L. Prchal, S. Fingler, M. Katalinić, Z. Kovarik, K. Musilek
520    9_
$a The fluorinated bis-pyridinium oximes were designed and synthesized with the aim of increasing their nucleophilicity and potential to reactivate phosphorylated human recombinant acetylcholinesterase (AChE) and human purified plasmatic butyrylcholinesterase (BChE) in relation to chlorinated and non-halogenated oxime analogues. Compared to non-halogenated oximes, halogenated oximes showed lower pKa of the oxime group (fluorinated < chlorinated < non-halogenated) along with higher level of oximate anion formation at the physiological pH, and had a higher binding affinity of both AChE and BChE. The stability tests showed that the fluorinated oximes were stable in water, while in buffered environment di-fluorinated oximes were prone to rapid degradation, which was reflected in their lower reactivation ability. Mono-fluorinated oximes showed comparable reactivation to non-halogenated (except asoxime) and mono-chlorinated oximes in case of AChE inhibited by sarin, cyclosarin, VX, and tabun, but were less efficient than di-chlorinated ones. The same trend was observed in the reactivation of inhibited BChE. The advantage of halogen substituents in the stabilization of oxime in a position optimal for in-line nucleophilic attack were confirmed by extensive molecular modelling of pre-reactivation complexes between the analogue oximes and phosphorylated AChE and BChE. Halogen substitution was shown to provide oximes with additional beneficial properties, e.g., fluorinated oximes gained antioxidative capacity, and moreover, halogens themselves did not increase cytotoxicity of oximes. Finally, the in vivo administration of highly efficient reactivator and the most promising analogue, 3,5-di-chloro-bispyridinium oxime with trimethylene linker, provided significant protection of mice exposed to sarin and cyclosarin.
650    _2
$a acetylcholinesterasa $x metabolismus $7 D000110
650    _2
$a zvířata $7 D000818
650    _2
$a butyrylcholinesterasa $x metabolismus $7 D002091
650    _2
$a cholinesterasové inhibitory $x chemie $7 D002800
650    12
$a reaktivátory cholinesterasy $x chemie $7 D002801
650    _2
$a halogeny $7 D006219
650    _2
$a myši $7 D051379
650    12
$a nervová bojová látka $x farmakologie $7 D000067397
650    _2
$a organofosforové sloučeniny $7 D009943
650    _2
$a oximy $x chemie $7 D010091
650    _2
$a sarin $x chemie $7 D012524
655    _2
$a časopisecké články $7 D016428
700    1_
$a Malinak, David $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 50003, Hradec Kralove, Czech Republic; Biomedical Research Center, University Hospital in Hradec Kralove, Sokolska 581, 50005, Hradec Kralove, Czech Republic
700    1_
$a Hofmanová, Tereza $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 50003, Hradec Kralove, Czech Republic $7 xx0278053
700    1_
$a Maraković, Nikola $u Institute for Medical Research and Occupational Health, Ksaverska Cesta 2, HR-10000, Zagreb, Croatia
700    1_
$a Žunec, Suzana $u Institute for Medical Research and Occupational Health, Ksaverska Cesta 2, HR-10000, Zagreb, Croatia
700    1_
$a Hrvat, Nikolina Maček $u Institute for Medical Research and Occupational Health, Ksaverska Cesta 2, HR-10000, Zagreb, Croatia
700    1_
$a Andrys, Rudolf $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 50003, Hradec Kralove, Czech Republic
700    1_
$a Psotka, Miroslav $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 50003, Hradec Kralove, Czech Republic; Biomedical Research Center, University Hospital in Hradec Kralove, Sokolska 581, 50005, Hradec Kralove, Czech Republic $7 xx0277934
700    1_
$a Zandona, Antonio $u Institute for Medical Research and Occupational Health, Ksaverska Cesta 2, HR-10000, Zagreb, Croatia
700    1_
$a Svobodová, Jana $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 50003, Hradec Kralove, Czech Republic $7 xx0145252
700    1_
$a Prchal, Lukas $u Biomedical Research Center, University Hospital in Hradec Kralove, Sokolska 581, 50005, Hradec Kralove, Czech Republic
700    1_
$a Fingler, Sanja $u Institute for Medical Research and Occupational Health, Ksaverska Cesta 2, HR-10000, Zagreb, Croatia
700    1_
$a Katalinić, Maja $u Institute for Medical Research and Occupational Health, Ksaverska Cesta 2, HR-10000, Zagreb, Croatia
700    1_
$a Kovarik, Zrinka $u Institute for Medical Research and Occupational Health, Ksaverska Cesta 2, HR-10000, Zagreb, Croatia. Electronic address: zkovarik@imi.hr
700    1_
$a Musilek, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 50003, Hradec Kralove, Czech Republic; Biomedical Research Center, University Hospital in Hradec Kralove, Sokolska 581, 50005, Hradec Kralove, Czech Republic. Electronic address: kamil.musilek@uhk.cz
773    0_
$w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 238, č. - (2022), s. 114377
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35526478 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20221025132930 $b ABA008
999    __
$a ok $b bmc $g 1821745 $s 1169034
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 238 $c - $d 114377 $e 20220427 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...